Rubius Therapeutics logo
Rubius Therapeutics RUBY

Annual report 2022
added 02-27-2023

report update icon

Rubius Therapeutics Net Debt 2011-2026 | RUBY

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Rubius Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-141 M -14.1 M 149 M -186 M -98.8 M -2.91 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
149 M -186 M -48.9 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.44 -4.32 % $ 1.03 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
ADMA Biologics ADMA Biologics
ADMA
-17.2 M $ 15.36 -2.17 % $ 3.66 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-206 M $ 3.53 -3.54 % $ 116 M franceFrance
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.28 0.65 % $ 2.56 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
-7.95 M - -19.68 % $ 18.4 M canadaCanada
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.79 -1.15 % $ 4.31 M chinaChina
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.51 1.35 % $ 385 M britainBritain
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
-13.4 M $ 2.01 -1.36 % $ 2.86 M chinaChina
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
-3.1 M $ 0.67 7.08 % $ 624 K israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
-46 M $ 14.05 -1.44 % $ 206 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
166 M $ 74.36 -1.64 % $ 1.44 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Athersys Athersys
ATHX
-27.6 M - 3.77 % $ 22.4 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-48 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 162.43 0.6 % $ 8.08 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
211 M $ 8.49 -0.18 % $ 1.75 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
1.44 B $ 65.66 -0.78 % $ 12.6 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
533 K - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-34.7 M - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
-60.5 M - -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-13.9 M $ 2.69 -0.74 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
-1.3 B $ 61.3 1.21 % $ 11.8 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 7.79 -5.75 % $ 1.28 B britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
-206 M - - $ 3.45 B usaUSA